MatMaCorp has announced efficacy data of its Covid-19 2SF RNA test when detecting SARS-CoV-2 variants. Preliminary evaluation of the data indicates that the test is capable of detecting more than 99.5% of the 3,801 coronavirus variants reported across the world till date.

Roche has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) for its SARS-CoV-2 rapid antigen test. The test is expected to be widely available in Germany and enables at-home self-testing by patients with the help of a simple nasal swab.

Therma Bright has entered into an agreement with a Covid-19 testing site in the Greater Toronto Area to conduct a clinical trial of its AcuVid rapid antigen test, a saliva-based Covid-19 test. The testing site is expected to have one of the highest positivity rates in Ontario.